Latest Anz Market News

Zip Co Limited (ASX: ZIP) reported a 46% rise in net profit to $116.4 million for FY26, driven by strong US and ANZ market growth and record cash earnings of $268.9 million. The company also announced an orderly wind down of its New Zealand operations to focus on its core markets.

Cyclopharm Limited delivered a record $17.1 million in revenue for 1H FY26, driven by a 73% surge in US Technegas® sales. However, delays in clinical guideline publication have pushed the short-term US installation target beyond 2026, while medium-term ambitions remain intact.

EROAD Limited reported stable FY26 revenue of NZD 195 million amid a $134.7 million North American impairment, unveiling a strategic reset centred on ANZ growth and its expanding electronic Road User Charges platform.

CleanSpace's AGILE respirator has achieved AS/NZS 17420.2:2021 certification, paving the way for commercialisation in Australia and New Zealand alongside its recent European approval.

EROAD reported flat group revenue of NZD 195.2 million for FY26, driven by strong Australian growth and steady New Zealand performance, offset by a North American decline and a hefty goodwill impairment.

Gratifii Limited has secured $10 million in new capital to acquire Simplicity Loyalty and invest strategically in Marketplacer, aiming to broaden its loyalty and rewards platform across Australia and New Zealand.

Aristocrat Leisure delivered a strong half-year profit surge with 16% growth in normalised NPATA on a constant currency basis, driven by market share gains and strategic investments, while declaring a 50c interim dividend.

Zip Co’s April update highlights robust US and ANZ market expansion, with total transaction volume surging and credit losses forecast below 1.75%. The company reconfirms FY26 guidance, underpinned by AI-driven underwriting and new subscription offerings.

Renowned boosts its US footprint with a landmark RE/MAX partnership and expands multi-year brokerage deals in Australia and New Zealand, driving 3% group revenue growth and positive cash flow in Q3 FY26.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Zip Co reported a 41.5% jump in third quarter cash EBTDA to $65.1 million, driven by accelerated US transaction volume growth of 43.1% and steady credit losses. The company upgraded its FY26 cash EBTDA guidance to at least $260 million, highlighting robust profitability and expanding customer engagement.